Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study Investigating the Safety and Efficacy of Autologous TAC T Cells in Subjects With Unresectable, Locally Advanced or Metastatic Claudin 18.2+ Solid Tumors

NCT05862324 is registered in ClinicalTrials.gov with Triumvira Immunologics, Inc. as lead sponsor.

NCT NCT05862324
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05862324 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study Investigating the Safety and Efficacy of Autologous TAC T Cells in Subjects With Unresectable, Locally Advanced or Metastatic Claudin 18.2+ Solid Tumors
Lead sponsor
Triumvira Immunologics, Inc.
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
August 23, 2023
Completion date
August 1, 2027
Enrollment
113 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic solid tumor